Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""ATAZANAVIR"" wg kryterium: Temat


Tytuł :
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Autorzy :
Kalantari S; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.; Department of Infectious Diseases, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Fard SR; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
Maleki D; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.; Department of Infectious Diseases, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Taher MT; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.; Department of Infectious Diseases, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Yassin Z; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.; Department of Infectious Diseases, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Alimohamadi Y; Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran.
Minaeian S; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
Journal of medical virology [J Med Virol] 2021 Dec; Vol. 93 (12), pp. 6557-6565. Date of Electronic Publication: 2021 Jul 28.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*therapeutic use
Atazanavir Sulfate/*therapeutic use
COVID-19/*drug therapy
Heterocyclic Compounds, 3-Ring/*therapeutic use
Hydroxychloroquine/*therapeutic use
Lopinavir/*therapeutic use
Oxazines/*therapeutic use
Piperazines/*therapeutic use
Pyridones/*therapeutic use
Ritonavir/*therapeutic use
Antiviral Agents/administration & dosage ; Atazanavir Sulfate/administration & dosage ; COVID-19/pathology ; Drug Combinations ; Drug Therapy, Combination ; Female ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Humans ; Hydroxychloroquine/administration & dosage ; Lopinavir/administration & dosage ; Male ; Middle Aged ; Oxazines/administration & dosage ; Piperazines/administration & dosage ; Pyridones/administration & dosage ; Ritonavir/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review.
Autorzy :
Ridjab DA; School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
Ivan I
Budiman F
Juliawati DJ
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Aug 06; Vol. 100 (31), pp. e26787.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Atazanavir Sulfate/*adverse effects
Long QT Syndrome/*etiology
Lopinavir/*adverse effects
Ritonavir/*adverse effects
Saquinavir/*adverse effects
Adult ; Atazanavir Sulfate/therapeutic use ; Cytochrome P-450 CYP3A Inhibitors/adverse effects ; Drug Therapy, Combination/methods ; Drug Therapy, Combination/standards ; Electrocardiography/methods ; Humans ; Lopinavir/therapeutic use ; Ritonavir/therapeutic use ; Saquinavir/therapeutic use
Czasopismo naukowe
Tytuł :
Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
Autorzy :
Olagunju A; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria. .; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom. .
Fowotade A; Department of Medical Microbiology and Parasitology, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Olagunoye A; State Specialist Hospital, Osogbo, Nigeria.
Ojo TO; Department of Community Health, Faculty of Clinical Sciences, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria.
Adefuye BO; Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.
Fagbamigbe AF; Department of Epidemiology and Medical Statistics, Faculty of Public Health, University of Ibadan, Ibadan, Nigeria.
Adebiyi AO; Department of Community Medicine, University of Ibadan, Ibadan, Nigeria.
Olagunju OI; Department of Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Nigeria.
Ladipo OT; Oyo State Ministry of Health, Ibadan, Nigeria.
Akinloye A; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria.
Adeagbo BA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria.
Onayade A; Department of Community Health, Faculty of Clinical Sciences, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria.
Bolaji OO; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria.
Happi C; African Centre of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Nigeria.
Rannard S; Department of Chemistry, School of Physical Sciences, University of Liverpool, Liverpool, United Kingdom.
Owen A; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Pokaż więcej
Źródło :
Trials [Trials] 2021 Jan 04; Vol. 22 (1), pp. 3. Date of Electronic Publication: 2021 Jan 04.
Typ publikacji :
Clinical Trial Protocol; Comparative Study; Letter
MeSH Terms :
Antiviral Agents/*administration & dosage
Atazanavir Sulfate/*administration & dosage
COVID-19/*drug therapy
Ritonavir/*administration & dosage
Thiazoles/*administration & dosage
Administration, Oral ; Adolescent ; Adult ; Aged ; Antiviral Agents/adverse effects ; Atazanavir Sulfate/adverse effects ; COVID-19/diagnosis ; COVID-19/virology ; COVID-19 Nucleic Acid Testing ; Clinical Trials, Phase II as Topic ; Drug Administration Schedule ; Drug Combinations ; Drug Repositioning ; Drug Therapy, Combination/adverse effects ; Drug Therapy, Combination/methods ; Female ; Humans ; Male ; Middle Aged ; Multicenter Studies as Topic ; Nigeria ; Pilot Projects ; RNA, Viral/isolation & purification ; Randomized Controlled Trials as Topic ; Ritonavir/adverse effects ; SARS-CoV-2/drug effects ; SARS-CoV-2/isolation & purification ; Severity of Illness Index ; Standard of Care ; Thiazoles/adverse effects ; Treatment Outcome ; Viral Load/drug effects ; Young Adult
SCR Protocol :
COVID-19 drug treatment
Raport
Tytuł :
Cardiovascular risks associated with protease inhibitors for the treatment of HIV.
Autorzy :
Hatleberg CI; Department of Infectious Diseases, Centre of Excellence for Health, Immunity and Infections (CHIP), Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Ryom L; Department of Infectious Diseases, Centre of Excellence for Health, Immunity and Infections (CHIP), Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Sabin C; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health,University College London, London, UK.
Pokaż więcej
Źródło :
Expert opinion on drug safety [Expert Opin Drug Saf] 2021 Nov; Vol. 20 (11), pp. 1351-1366. Date of Electronic Publication: 2021 Jul 26.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Cardiovascular Diseases/*etiology
HIV Infections/*drug therapy
HIV Protease Inhibitors/*adverse effects
Animals ; Atazanavir Sulfate/administration & dosage ; Atazanavir Sulfate/adverse effects ; Atherosclerosis/etiology ; Darunavir/administration & dosage ; Darunavir/adverse effects ; Dyslipidemias/chemically induced ; Dyslipidemias/complications ; HIV Protease Inhibitors/administration & dosage ; Heart Disease Risk Factors ; Humans ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
(Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration.
Autorzy :
Subbaiah MAM; Department of Medicinal Chemistry (Prodrug Group), Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, India. Electronic address: .
Ramar T; Department of Medicinal Chemistry (Prodrug Group), Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, India.
Subramani L; Department of Medicinal Chemistry (Prodrug Group), Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, India.
Desai SD; Department of Biopharmaceutics, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, India.
Sinha S; Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, India.
Mandlekar S; Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, India.
Jenkins SM; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.
Krystal MR; Department of Virology, Bristol Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.
Subramanian M; Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, India.
Sridhar S; Department of Biopharmaceutics, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, India.
Padmanabhan S; Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, India.
Bhutani P; Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, India.
Arla R; Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, India.
Kadow JF; Department of Small Molecule Drug Discovery, Bristol Myers Squibb Research and Development, PO Box 4000, Princeton, NJ, 08543-4000, United States.
Meanwell NA; Department of Small Molecule Drug Discovery, Bristol Myers Squibb Research and Development, PO Box 4000, Princeton, NJ, 08543-4000, United States.
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2020 Dec 01; Vol. 207, pp. 112749. Date of Electronic Publication: 2020 Aug 21.
Typ publikacji :
Journal Article
MeSH Terms :
Amino Acids/*chemistry
Atazanavir Sulfate/*pharmacokinetics
Atazanavir Sulfate/*pharmacology
HIV Protease/*metabolism
HIV Protease Inhibitors/*pharmacokinetics
HIV Protease Inhibitors/*pharmacology
Prodrugs/*chemistry
Alkylation ; Amines/chemistry ; Amino Acids/metabolism ; Atazanavir Sulfate/blood ; Atazanavir Sulfate/metabolism ; Biological Availability ; Drug Stability ; HIV Protease Inhibitors/blood ; HIV Protease Inhibitors/metabolism ; Humans ; Prodrugs/metabolism
Czasopismo naukowe
Tytuł :
Cellular Mechanism Underlying Highly-Active or Antiretroviral Therapy-Induced Lipodystrophy: Atazanavir, a Protease Inhibitor, Compromises Adipogenic Conversion of Adipose-Derived Stem/Progenitor Cells through Accelerating ER Stress-Mediated Cell Death in Differentiating Adipocytes.
Autorzy :
Akita S; Department of Plastic Surgery, Wound Repair and Regeneration, School of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.; Department of Plastic and Reconstructive Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
Suzuki K; Department of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
Yoshimoto H; Department of Plastic and Reconstructive Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
Ohtsuru A; Takashi Nagai Memorial International Hibakusha Medical Center, Nagasaki University Graduate School of Biomedical Science, 1-12-4 Nagasaki, Nagasaki852-8523, Japan.
Hirano A; Department of Plastic and Reconstructive Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
Yamashita S; Department of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.; Takashi Nagai Memorial International Hibakusha Medical Center, Nagasaki University Graduate School of Biomedical Science, 1-12-4 Nagasaki, Nagasaki852-8523, Japan.; Fukushima Medical University School of Medicine, 1 Hikariga-oka, Fukushima 960-1295, Japan.; Center for Advanced Radiation Emergency Medicine at the National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Feb 20; Vol. 22 (4). Date of Electronic Publication: 2021 Feb 20.
Typ publikacji :
Journal Article
MeSH Terms :
Adipogenesis*/drug effects
Cell Differentiation*/drug effects
Endoplasmic Reticulum Stress*/drug effects
Adipocytes/*pathology
Anti-Retroviral Agents/*adverse effects
Atazanavir Sulfate/*therapeutic use
Lipodystrophy/*chemically induced
Stem Cells/*pathology
Adipocytes/drug effects ; Adipocytes/metabolism ; Adipose Tissue/pathology ; Antiretroviral Therapy, Highly Active ; Apoptosis/drug effects ; Atazanavir Sulfate/pharmacology ; Cell Death/drug effects ; Cells, Cultured ; DNA Damage ; Humans ; Lipid Droplets/drug effects ; Lipid Droplets/metabolism ; Oxidative Stress/drug effects ; Protease Inhibitors/pharmacology ; Protease Inhibitors/therapeutic use ; Reactive Oxygen Species/metabolism ; Stem Cells/drug effects ; Stem Cells/metabolism ; Transcription Factor CHOP/metabolism
Czasopismo naukowe
Tytuł :
Higher plasma drug levels in elderly people living with HIV treated with darunavir.
Autorzy :
Tyrberg E; Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Region Västra Götaland, Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.
Edén A; Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Region Västra Götaland, Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.
Eriksen J; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.; Department of Infectious Diseases/Venhälsan, Stockholm South General Hospital, Stockholm, Sweden.
Nilsson S; Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden.
Treutiger CJ; Department of Infectious Diseases/Venhälsan, Stockholm South General Hospital, Stockholm, Sweden.
Thalme A; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Mellgren Å; Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Clinic of Infectious Diseases, South Älvsborg Hospital, Borås, Sweden.
Gisslén M; Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Region Västra Götaland, Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.
Andersson LM; Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Region Västra Götaland, Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2021 Feb 04; Vol. 16 (2), pp. e0246171. Date of Electronic Publication: 2021 Feb 04 (Print Publication: 2021).
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Alkynes/*blood
Anti-HIV Agents/*blood
Atazanavir Sulfate/*blood
Benzoxazines/*blood
Cyclopropanes/*blood
Darunavir/*blood
HIV Infections/*drug therapy
Adult ; Aged ; Alkynes/adverse effects ; Anti-HIV Agents/adverse effects ; Atazanavir Sulfate/adverse effects ; Benzoxazines/adverse effects ; Case-Control Studies ; Cross-Sectional Studies ; Cyclopropanes/adverse effects ; Darunavir/adverse effects ; Drug Interactions ; HIV Infections/blood ; Humans ; Male ; Middle Aged ; Plasma/chemistry ; Sweden
Czasopismo naukowe
Tytuł :
Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis.
Autorzy :
Cazzaniga A; General Pathology.
Scrimieri R; General Pathology.
Galli M; Infectious Diseases Unit, Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università degli Studi di Milano, Milan, Italy.
Maier J; General Pathology.
Rusconi S; Infectious Diseases Unit, Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università degli Studi di Milano, Milan, Italy.
Pokaż więcej
Źródło :
AIDS (London, England) [AIDS] 2021 Feb 02; Vol. 35 (2), pp. 213-218.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-HIV Agents*/adverse effects
Bone Diseases, Metabolic*/chemically induced
HIV Infections*/complications
HIV Infections*/drug therapy
Atazanavir Sulfate/*adverse effects
Darunavir/*adverse effects
Heterocyclic Compounds, 3-Ring/*adverse effects
Oxazines/*adverse effects
Piperazines/*adverse effects
Pyridones/*adverse effects
Atazanavir Sulfate/therapeutic use ; Darunavir/therapeutic use ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Osteogenesis ; Oxazines/therapeutic use ; Piperazines/therapeutic use ; Pyridones/therapeutic use
Czasopismo naukowe
Tytuł :
An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Autorzy :
Walimbwa, Stephen I. (AUTHOR)
Kaboggoza, Julian P. (AUTHOR)
Waitt, Catriona (AUTHOR)
Byakika-Kibwika, Pauline (AUTHOR)
D'Avolio, Antonio (AUTHOR)
Lamorde, Mohammed (AUTHOR)
Pokaż więcej
Źródło :
Trials. 11/23/2021, Vol. 22 Issue 1, p1-13. 13p. 1 Diagram, 3 Charts.
Czasopismo naukowe
Tytuł :
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
Autorzy :
Rahmani H; Department of Pharmacotherapy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Davoudi-Monfared E; Department of Pharmacotherapy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Nourian A; Department of Pharmacotherapy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Nabiee M; Department of Pharmacotherapy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Sadeghi S; Department of Pharmacotherapy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Khalili H; Department of Pharmacotherapy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. .
Abbasian L; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Ghiasvand F; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Seifi A; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Hasannezhad M; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Ghaderkhani S; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Mohammadi M; Department of Intensive Care Unit, Imam Khomeini Hospital Complex, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Yekaninejad MS; Department of Epidemiology and Biostatistics, School of Public health, Tehran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences [Daru] 2020 Dec; Vol. 28 (2), pp. 625-634. Date of Electronic Publication: 2020 Aug 28.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Atazanavir Sulfate/*administration & dosage
COVID-19/*drug therapy
Hydroxychloroquine/*administration & dosage
Ritonavir/*administration & dosage
Adult ; Aged ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Atazanavir Sulfate/adverse effects ; COVID-19/mortality ; COVID-19/virology ; Drug Therapy, Combination ; Female ; Hospitalization/statistics & numerical data ; Humans ; Hydroxychloroquine/adverse effects ; Intensive Care Units/statistics & numerical data ; Length of Stay ; Male ; Middle Aged ; Prospective Studies ; Ritonavir/adverse effects ; Severity of Illness Index ; Time Factors ; Treatment Outcome
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Decoding molecular mechanism underlying binding of drugs to HIV-1 protease with molecular dynamics simulations and MM-GBSA calculations.
Autorzy :
Yu YX; School of Science, Shandong Jiaotong University, Jinan, China.
Liu WT; Shuifa Qilu Cultural Tourism Development Co., Ltd, Shuifa Ecological Industry Group, Jinan, China.
Li HY; School of Science, Shandong Jiaotong University, Jinan, China.
Wang W; School of Science, Shandong Jiaotong University, Jinan, China.
Sun HB; School of Science, Shandong Jiaotong University, Jinan, China.
Zhang LL; School of Science, Shandong Jiaotong University, Jinan, China.
Wu SL; School of Science, Shandong Jiaotong University, Jinan, China.
Pokaż więcej
Źródło :
SAR and QSAR in environmental research [SAR QSAR Environ Res] 2021 Nov; Vol. 32 (11), pp. 889-915. Date of Electronic Publication: 2021 Sep 23.
Typ publikacji :
Journal Article
MeSH Terms :
Molecular Dynamics Simulation*
Anti-HIV Agents/*metabolism
Atazanavir Sulfate/*metabolism
HIV Protease/*metabolism
Lopinavir/*metabolism
Nelfinavir/*metabolism
Binding Sites
Czasopismo naukowe
Tytuł :
Identifying side effects of commonly used drugs in the treatment of Covid 19.
Autorzy :
Aygün İ; Department of Software Engineering, Celal Bayar University, Manisa, Turkey.
Kaya M; Department of Computer Engineering, Fırat University, Elazığ, Turkey.
Alhajj R; Department of Computer Science, University of Calgary, Calgary, AB, Canada. .; Department of Computer Engineering, Isstanbul Medipol University, Istanbul, Turkey. .; Department of Health Informatics, University of Southern Denmark, Odense, Denmark. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Dec 09; Vol. 10 (1), pp. 21508. Date of Electronic Publication: 2020 Dec 09.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Atazanavir Sulfate/*therapeutic use
COVID-19/*drug therapy
COVID-19/*metabolism
Heparin/*therapeutic use
SARS-CoV-2/*metabolism
Atazanavir Sulfate/adverse effects ; COVID-19/pathology ; Drug Interactions ; Heparin/adverse effects ; Humans
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
In utero exposure to protease inhibitor-based antiretroviral regimens delays growth and developmental milestones in mice.
Autorzy :
Sarkar A; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
Balogun K; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
Guzman Lenis MS; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
Acosta S; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
Mount HT; Departments of Psychiatry & Physiology, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.; Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.
Serghides L; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.; Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.; Women's College Research Institute, Toronto, Ontario, Canada.; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Nov 19; Vol. 15 (11), pp. e0242513. Date of Electronic Publication: 2020 Nov 19 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Prenatal Exposure Delayed Effects*
Atazanavir Sulfate/*toxicity
Developmental Disabilities/*chemically induced
Exploratory Behavior/*drug effects
Growth Disorders/*chemically induced
HIV Protease Inhibitors/*toxicity
Animals ; Anti-HIV Agents/administration & dosage ; Atazanavir Sulfate/administration & dosage ; Dideoxynucleosides/administration & dosage ; Dideoxynucleosides/toxicity ; Emtricitabine/administration & dosage ; Emtricitabine/toxicity ; Female ; Fetal Growth Retardation/chemically induced ; HIV Protease Inhibitors/administration & dosage ; Hand Strength ; Homing Behavior/drug effects ; Lamivudine/administration & dosage ; Lamivudine/toxicity ; Male ; Mice ; Mice, Inbred C57BL ; Pregnancy ; Random Allocation ; Reflex, Abnormal ; Reflex, Righting/drug effects ; Sensation Disorders/chemically induced ; Taxis Response/drug effects ; Tenofovir/administration & dosage ; Tenofovir/toxicity
Czasopismo naukowe
Tytuł :
Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
Autorzy :
Li M; Division of Gastroenterology, Hepatology, and Endoscopy Brigham & Women's Hospital Boston MA.; Harvard Medical School Boston MA.
Chan WW; Division of Gastroenterology, Hepatology, and Endoscopy Brigham & Women's Hospital Boston MA.; Harvard Medical School Boston MA.
Zucker SD; Division of Gastroenterology, Hepatology, and Endoscopy Brigham & Women's Hospital Boston MA.; Harvard Medical School Boston MA.
Pokaż więcej
Źródło :
Journal of the American Heart Association [J Am Heart Assoc] 2020 Oct 20; Vol. 9 (19), pp. e016310. Date of Electronic Publication: 2020 Sep 15.
Typ publikacji :
Journal Article
MeSH Terms :
Atazanavir Sulfate/*adverse effects
Cardiovascular Diseases/*prevention & control
HIV Infections/*drug therapy
HIV Protease Inhibitors/*therapeutic use
Hyperbilirubinemia/*chemically induced
Atazanavir Sulfate/therapeutic use ; Bilirubin/blood ; Darunavir/therapeutic use ; Female ; HIV Infections/complications ; Humans ; Ischemic Stroke/epidemiology ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Myocardial Infarction/epidemiology ; Proportional Hazards Models ; Retrospective Studies ; Time Factors
Czasopismo naukowe
Tytuł :
First step to the improvement of the blood brain barrier passage of atazanavir encapsulated in sustainable bioorganic vesicles.
Autorzy :
Nolay F; LG2A UMR CNRS 7378 Institut de Chimie de Picardie FR CNRS 3085, SFR Condorcet, Université de Picardie Jules Verne, 33 Rue St Leu, 80039 Amiens, France.
Sevin E; Univ. Artois, UR2465, BBB Laboratory, 62300 Lens, France.
Létévé M; LG2A UMR CNRS 7378 Institut de Chimie de Picardie FR CNRS 3085, SFR Condorcet, Université de Picardie Jules Verne, 33 Rue St Leu, 80039 Amiens, France.
Bil A; LG2A UMR CNRS 7378 Institut de Chimie de Picardie FR CNRS 3085, SFR Condorcet, Université de Picardie Jules Verne, 33 Rue St Leu, 80039 Amiens, France.
Gosselet F; Univ. Artois, UR2465, BBB Laboratory, 62300 Lens, France.
El Kirat K; BMBI UMR CNRS 7338 Centre de Recherche Royallieu, Université de Technologie de Compiègne, 60203 Compiègne, France.
Djedaini-Pilard F; LG2A UMR CNRS 7378 Institut de Chimie de Picardie FR CNRS 3085, SFR Condorcet, Université de Picardie Jules Verne, 33 Rue St Leu, 80039 Amiens, France.
Morandat S; GEC FRE CNRS 3580 Centre de Recherche Royallieu, Université de Technologie de Compiègne, 60203 Compiègne, France.
Fenart L; Univ. Artois, UR2465, BBB Laboratory, 62300 Lens, France.
Przybylski C; Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire, IPCM, 4 Place Jussieu, 75005 Paris, France.
Bonnet V; LG2A UMR CNRS 7378 Institut de Chimie de Picardie FR CNRS 3085, SFR Condorcet, Université de Picardie Jules Verne, 33 Rue St Leu, 80039 Amiens, France. Electronic address: .
Pokaż więcej
Źródło :
International journal of pharmaceutics [Int J Pharm] 2020 Sep 25; Vol. 587, pp. 119604. Date of Electronic Publication: 2020 Jul 12.
Typ publikacji :
Journal Article
MeSH Terms :
Atazanavir Sulfate*
Blood-Brain Barrier*
Cyclodextrins*
Nanoparticles*
Animals ; Cattle ; Cells, Cultured ; Endothelial Cells ; Rats
Czasopismo naukowe
Tytuł :
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Autorzy :
Fintelman-Rodrigues N; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Sacramento CQ; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Ribeiro Lima C; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Souza da Silva F; Laboratório de Biologia Molecular e Doenças Endêmicas, IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Ferreira AC; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.; Universidade Iguaçu, Nova Iguaçu, Rio de Janeiro, Brazil.; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Mattos M; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
de Freitas CS; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Cardoso Soares V; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.
da Silva Gomes Dias S; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.
Temerozo JR; Laboratório de Pesquisas sobre o Timo, IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.; National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Miranda MD; Laboratório de Vírus Respiratório e do Sarampo, IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Matos AR; Laboratório de Vírus Respiratório e do Sarampo, IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Bozza FA; Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.; Instituto D'or de Pesquisa e Ensino, Rio de Janeiro, Rio de Janeiro, Brazil.
Carels N; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Alves CR; Laboratório de Biologia Molecular e Doenças Endêmicas, IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Siqueira MM; Laboratório de Vírus Respiratório e do Sarampo, IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Bozza PT; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.
Souza TML; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil .; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Pokaż więcej
Źródło :
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2020 Sep 21; Vol. 64 (10). Date of Electronic Publication: 2020 Sep 21 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*pharmacology
Atazanavir Sulfate/*pharmacology
Betacoronavirus/*drug effects
Cytokines/*metabolism
Ritonavir/*pharmacology
Animals ; Atazanavir Sulfate/chemistry ; Betacoronavirus/pathogenicity ; Betacoronavirus/physiology ; COVID-19 ; Cell Death/drug effects ; Chlorocebus aethiops ; Coronavirus 3C Proteases ; Coronavirus Infections/drug therapy ; Coronavirus Infections/metabolism ; Coronavirus Infections/pathology ; Cysteine Endopeptidases/chemistry ; Cysteine Endopeptidases/metabolism ; Drug Therapy, Combination ; Humans ; Inflammation/metabolism ; Inflammation/virology ; Lopinavir/pharmacology ; Molecular Docking Simulation ; Monocytes/virology ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/metabolism ; Pneumonia, Viral/pathology ; Protease Inhibitors/pharmacology ; SARS-CoV-2 ; Vero Cells ; Viral Nonstructural Proteins/antagonists & inhibitors ; Viral Nonstructural Proteins/chemistry ; Viral Nonstructural Proteins/metabolism ; Virus Replication/drug effects
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects.
Autorzy :
Hens B; Drug Delivery and Disposition, KU Leuven, Leuven, Belgium.
Masuy I; Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium.
Deloose E; Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium.
Mols R; Drug Delivery and Disposition, KU Leuven, Leuven, Belgium.
Tack J; Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium.
Augustijns P; Drug Delivery and Disposition, KU Leuven, Leuven, Belgium. Electronic address: .
Pokaż więcej
Źródło :
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2020 May; Vol. 150, pp. 66-76. Date of Electronic Publication: 2020 Feb 28.
Typ publikacji :
Journal Article
MeSH Terms :
Gastric Emptying*
Intestinal Absorption*
Atazanavir Sulfate/*administration & dosage
Atazanavir Sulfate/*pharmacokinetics
HIV Protease Inhibitors/*administration & dosage
HIV Protease Inhibitors/*pharmacokinetics
Administration, Oral ; Adult ; Atazanavir Sulfate/blood ; Carbonated Beverages ; Cross-Over Studies ; Drug Stability ; Female ; Gastric Acid/metabolism ; HIV Protease Inhibitors/blood ; Healthy Volunteers ; Humans ; Hydrogen-Ion Concentration ; Male ; Middle Aged ; Solubility ; Water/chemistry ; Young Adult
Czasopismo naukowe
Tytuł :
Quantum simulations of SARS-CoV-2 main protease M enable high-quality scoring of diverse ligands.
Autorzy :
Wang Y; Quantum Simulation Technologies, Inc, 625 Massachusetts Ave, Floor 2, Cambridge, MA, 02139, USA.
Murlidaran S; Quantum Simulation Technologies, Inc, 625 Massachusetts Ave, Floor 2, Cambridge, MA, 02139, USA.
Pearlman DA; Quantum Simulation Technologies, Inc, 625 Massachusetts Ave, Floor 2, Cambridge, MA, 02139, USA. .
Pokaż więcej
Źródło :
Journal of computer-aided molecular design [J Comput Aided Mol Des] 2021 Sep; Vol. 35 (9), pp. 963-971. Date of Electronic Publication: 2021 Jul 30.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents/*chemistry
Coronavirus 3C Proteases/*chemistry
Coronavirus 3C Proteases/*metabolism
Antiviral Agents/metabolism ; Atazanavir Sulfate/chemistry ; Atazanavir Sulfate/metabolism ; Binding Sites ; Cloud Computing ; Density Functional Theory ; Hydrogen Bonding ; Ligands ; Molecular Docking Simulation ; Protein Conformation ; Quantum Theory
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies